$703M deal: Teva completes final divestiture of women's health products

Teva Pharmaceutical Industries Ltd. completed the $703 million sale of a portfolio of products within its global women ’s health business to CVC Capital Partners. The portfolio of products, all marketed and sold outside the United States, includes: the fertility treatment Ovaleap, the oral contraceptives Zoely and Seasonique, and the osteoporsis drug Actonel. The products will be sold by Theramex, previously a Teva women's health unit based in Monaco. CVC Capital Partners brought in former Allergan…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news